In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Shingrix is approved to prevent shingles ... immune response when the vaccines were co-administered compared to when they were administered at separate visits. Co-administration was also well ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety profiles, GSK said. The most frequently reported adverse events were ...

The data showed a non-inferior immune response when the vaccines were co-administered compared to when they were administered at separate visits. Co-administration was well tolerated. The company ...

These two reports address the effects of varicella-zoster ... vaccine recipients than among placebo recipients (0.6% vs. 0.4%), for unknown reasons. The review authors recommend vaccine ...

The P.E.I. government has lowered the age requirement for a free shingles vaccine to 50. The change from age 60 was announced in a news release Monday morning and is effective immediately.

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...